The estimated Net Worth of Scott R. Ward is at least $16.5 Milhão dollars as of 20 May 2022. Mr. Ward owns over 3,000 units of Cardiovascular Systems stock worth over $11,614,260 and over the last 14 years he sold CSII stock worth over $168,137. In addition, he makes $4,718,960 as Chairman of the Board, President, e Chief Executive Officer at Cardiovascular Systems.
Scott has made over 8 trades of the Cardiovascular Systems stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of CSII stock worth $43,470 on 20 May 2022.
The largest trade he's ever made was selling 5,529 units of Cardiovascular Systems stock on 17 August 2017 worth over $168,137. On average, Scott trades about 486 units every 59 days since 2010. As of 20 May 2022 he still owns at least 580,713 units of Cardiovascular Systems stock.
You can see the complete history of Mr. Ward stock trades at the bottom of the page.
Scott R. Ward serves as Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Ward has been a member of our Board of Directors since November 2013 and has served as its Chairman since November 2014. Mr. Ward served as our Interim President and Chief Executive Officer beginning November 30, 2015, and on August 15, 2016, Mr. Ward was appointed as our President and Chief Executive Officer. Since 2013, Mr. Ward has been one of the Managing Directors at SightLine Partners. Following his appointment as our President and Chief Executive Officer, Mr. Ward continues to be a Managing Director of Sightline Opportunity Management Fund II, LLC and may provide limited advisory and consulting services to Sightline Partners in this capacity. From 1981 to 2010, Mr. Ward was employed by Medtronic, Inc. and held a number of senior leadership positions. Mr. Ward was Senior Vice President and President of Medtronic’s CardioVascular business from May 2007 to November 2010. Prior to that he was Senior Vice President and President of Medtronic’s Vascular business from May 2004 to May 2007, Senior Vice President and President of Medtronic’s Neurological and Diabetes business, from February 2002 to May 2004, and President of Medtronic’s Neurological business from January 2000 to January 2002. He was Vice President and General Manager of Medtronic’s Drug Delivery business from 1995 to 2000. Prior to that, Mr. Ward led Medtronic’s Neurological Ventures in the successful development of new therapies. Mr. Ward serves on the boards of several private companies. Until April 2016, Mr. Ward was the Chairman of the Board of Creganna Medical. Mr. Ward served as a member of the Board of Surmodics, Inc. from September 2010 to March 2015.
As the Chairman of the Board, President, e Chief Executive Officer of Cardiovascular Systems, the total compensation of Scott Ward at Cardiovascular Systems is $4,718,960. There are no executives at Cardiovascular Systems getting paid more.
Scott Ward is 60, he's been the Chairman of the Board, President, e Chief Executive Officer of Cardiovascular Systems since 2016. There are 5 older and 18 younger executives at Cardiovascular Systems. The oldest executive at Cardiovascular Systems Inc. is Augustine Lawlor, 64, who is the Independent Director.
Scott's mailing address filed with the SEC is 1225 OLD HIGHWAY 8 NW, , ST. PAUL, MN, 55112.
Over the last 16 years, insiders at Cardiovascular Systems have traded over $72,999,461 worth of Cardiovascular Systems stock and bought 949,532 units worth $8,687,068 . The most active insiders traders include Capital Management Lp Camber, Augustine Lawlor, eCapital Ltdmaverick Capital.... On average, Cardiovascular Systems executives and independent directors trade stock every 14 days with the average trade being worth of $338,920. The most recent stock trade was executed by Martha Goldberg Aronson on 15 August 2022, trading 2,411 units of CSII stock currently worth $48,220.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.
Cardiovascular Systems executives and other stock owners filed with the SEC include: